Actelion shares fall on report it rejects J&J offer

November 30, 2016 11:52 AM EST

A general view shows Swiss biotech group Actelion Headquarters in Allschwil near Basel February 17, 2015. REUTERS/Arnd Wiegmann


Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

ZURICH (Reuters) - Shares in Swiss biotech company Actelion fell more than 6 percent after news outlet streetinsider.com reported on Wednesday the company had rejected a full takeover offer by U.S. healthcare group Johnson & Johnson and may sell a unit.

Actelion declined to comment on the report, which cited an unidentified source, and referred to a statement the company had published on Friday. The companies had confirmed last week they were in talks about a possible transaction.

(Reporting by Paul Arnold, Editing by Michael Shields)



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Reuters

Add Your Comment